Reviewing the Present State of Development of Senomorphic Therapies
Senescent cells accumulate with age and contribute to degenerative aging via their pro-growth, pro-inflammatory signaling. Even when less than 1% of all cells are senescent in a tissue, the signaling generated by those senescent cells alters the behavior of other cells for the worse, and is disruptive to tissue structure and function. When it comes to what to do about the burden of senescent cells in aged tissues, much of the focus is on the development of senolytic drugs that can selectively destroy these errant cells to some degree. The most popular alternative path is the development of senomorphic drugs that can suppress senescent cell signaling to some degree, but unlike the senolytic development community this cannot yet boast the large number of companies dedicated to producing novel drugs.
Just as there are a great many senolytic compounds in the small molecule libraries and even among presently approved small molecule drugs, there are also a great many senomorphic compounds. Quality varies widely, and, sadly, all too few outperform the effects of lifestyle choices on the burden and behavior of senescent cells. Those that do are relatively neglected by the medical and development communities because they are cheap and out of patent protection; there is not enough profit to be made to support the high costs of clinical trials. So even relative well-known senomorphics like rapamycin are far less widely used than they might be, and it is left to the very slow pace of the academic community to scrape up sufficient funds to conduct large-enough clinical trials to convince more physicians to prescribe for their patients.
Senomorphics are drugs that have to be used continuously, and are unlikely to suppress all problem signaling. Senolytics are drugs that can be used intermittently, and are unlikely to kill all senescent cells. There are clearly trade-offs of cost and convenience in addition to the debates over the potential side-effects of continuously altered senescent cell behavior versus destruction of cells that may be generating harm, but may also be propping up a tissue's structure. For example, what happens when destroying senescent cells broadly in an individual with severe atherosclerotic plaques in which a sizable fraction of cells are senescent? These debates are so far largely conducted in the absence of firm data, and that will likely continue to be the case until both approaches are more widely used in humans.
Cellular senescence serves as a pivotal driver of organismal ageing and its associated pathologies. This detrimental effect is primarily mediated through the secretion of a complex mixture of inflammatory factors, proteases, and other bioactive molecules, collectively termed the senescence-associated secretory phenotype (SASP), which promotes the onset and progression of multiple age-related diseases. Targeting this pathological process, the field of senotherapeutics has recently evolved two principal strategies: senolytics and senomorphic agents.
Senomorphic agents have emerged as a complementary or alternative strategy with distinct advantages. The core principle of this approach is to modulate, rather than eliminate, the function of senescent cells. By inhibiting key signaling pathways such as NF-κB, mTOR, and JAK/STAT, senomorphic agents directly curb the production of the deleterious SASP. This strategy may attenuate inflammation and tissue damage while potentially preserving certain physiological functions of senescent cells. However, the optimal balance between senolytic "clearance" and senomorphic "modulation" remains undefined, and the translational path for both strategies is fraught with challenges that have not been systematically addressed in the literature.
The present review offers three distinctive perspectives. First, we conceptualize the SASP-regulatory network as a hierarchical architecture - from upstream stress sensors to downstream epigenetic effectors - providing a systematic framework for understanding where and how senomorphic agents intervene. This framework is novel in that no prior review has explicitly organized the SASP-regulatory pathways into functional layers. Second, we critically analyze the translational barriers that have received insufficient attention in the existing literature, including the limitations of animal models, the lack of gerodiagnostic biomarkers, and the challenges of tissue-specific delivery. Third, we propose a disease-stage-adapted strategy that integrates senomorphic modulation with senolytic clearance, moving beyond the "either-or" debate toward a synergistic, precision-based paradigm. By bridging mechanistic insights with translational realities, this review aims not only to summarize the current state of the field but also to chart a roadmap for future clinical development of senomorphic therapies.